UBS’s Fortress Biotech FBIO Stock Holding History

UBS’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-47	Closed	-$1.24K	–	10530
2014 Q1	$1K	Sell	47 -20	-30%	-$780	﹤0.01%	10199
2013 Q4	$3K	Sell	67 -107	-61%	-$4.13K	﹤0.01%	9853
2013 Q3	$19K	Sell	174 -256	-60%	-$31.4K	﹤0.01%	8125
2013 Q2	$56K	Buy	+430	New	+$63.4K	﹤0.01%	6595

Other funds holding FBIO

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS's FBIO Position: Q2 2014 in Review

UBS sold out of Fortress Biotech (FBIO) in Q2 2014, closing a stake of 47 shares — an estimated $1.24K sold.

UBS first reported a position in FBIO in Q2 2013 and held it in 4 quarters. The position peaked at $56K in Q2 2013. 48 funds tracked by Wall St. Rank hold FBIO as of Q2 2014.

UBS reported no remaining Fortress Biotech position as of Q2 2014 after selling out during the quarter.
UBS sold 47 Fortress Biotech shares in Q2 2014, an estimated $1.24K.
UBS first reported a position in Fortress Biotech in Q2 2013 and held it in 4 quarters.
UBS's Fortress Biotech position peaked at $56K in Q2 2013.
48 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.